Unmasking a B-Cell Linkage Phenotype in Severe Acute Meningoencephalitis: A Case Report of IVIG and HydroBox-assisted Immunomodulatory Therapy Authors: CHANG-LUNG WU, JENG-WEI LU, YI-JUNG HO, MING-CHU WU, SHAN-WEN LUI, TING-YU HSIEH, WUN-LONG JHENG, FENG-CHENG LIU Published: 2026 ABSTRACT Background/AimSevere acute meningoencephalitis is a life-threatening neurological condition frequently associated with excessive inflammation, immune dysregulation, and secondary immune dysfunction. Immune exhaustion and abnormal immune cell remodeling may contribute to persistent inflammation and impaired recovery. Molecular hydrogen has emerged as a potential adjunctive therapy due to its selective antioxidant and immunomodulatory properties.Case ReportA previously healthy 30-year-old male developed fulminant acute meningoencephalitis complicated by coma, respiratory failure, and severe systemic inflammation. Longitudinal immune profiling revealed profound immune dysregulation, including extensive T-cell exhaustion-associated phenotypes, abnormal regulatory T-cell remodeling, and marked humoral immune activation. The patient demonstrated widespread expression of inhibitory immune checkpoint markers, accompanied by excessive plasmablast expansion and impaired antibody homeostasis. A combined therapeutic strategy consisting of standard intensive care, intravenous immunoglobulin (IVIG), and molecular hydrogen-based adjunctive therapy (HydroBox strategy) was initiated. Following intervention, systemic inflammation rapidly resolved, immune profiles progressively normalized, and neurological function recovered completely.ConclusionThis case highlights the dynamic relationship between acute neuroinflammation and systemic immune remodeling in severe meningoencephalitis. Longitudinal immunophenotyping may provide valuable insights into disease-associated immune dysfunction and therapeutic response. The combination of IVIG and molecular hydrogen-based adjunctive therapy may represent a potential strategy for restoring immune homeostasis in critical neuroinflammatory conditions, warranting further investigation. Introduction Acute severe meningoencephalitis represents a life-threatening neurological emergency characterized by extensive central nervous system inflammation and complex systemic immune dysregulation (1-3). Although infectious or autoimmune triggers initiate the inflammatory response, clinical deterioration is often driven by excessive immune activation, cytokine-mediated tissue injury, and disruption of immune homeostasis. During severe inflammatory states, persistent immune activation may paradoxically lead to a state of immune exhaustion, characterized by impaired immune cell function and increased expression of inhibitory checkpoint molecules. This phenomenon has been extensively described in chronic inflammatory conditions and is increasingly recognized as an important contributor to immune dysfunction during acute critical illnesses (4). The upregulation of inhibitory receptors, including programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin-domain containing-3 (Tim-3), together with senescence-associated markers such as killer cell lectin-like receptor G1 (KLRG1), reflects a transition toward dysfunctional immune regulation (5). In parallel, severe inflammatory responses may induce profound alterations in humoral immunity. Dysregulated B-cell activation and abnormal plasmablast expansion can contribute to excessive antibody-mediated inflammation and further aggravate systemic immune imbalance (6). Intravenous immunoglobulin (IVIG) has therefore been widely used as an immunomodulatory therapy due to its ability to regulate Fc-gamma receptor signaling, neutralize pathogenic antibodies, and modulate B-cell activity (7). However, IVIG alone may not fully restore cellular immune dysfunction, particularly when immune exhaustion and oxidative stress-induced metabolic impairment are present. Molecular hydrogen has emerged as a potential adjunctive therapy owing to its selective antioxidant and immunomodulatory properties. Recent mechanistic studies suggest that molecular hydrogen may influence cellular signaling through transient receptor potential cation channel subfamily C member 4 (TRPC4)/transient receptor potential cation channel subfamily C member 4 associated protein (TRPC4AP)-dependent calcium regulation and interact with mitochondrial electron transport components, including the Rieske iron-sulfur protein (RISP), thereby supporting mitochondrial homeostasis and cellular stress adaptation (8). Furthermore, recent clinical immunophenotyping studies indicate that hydrogen-assisted therapy may modulate abnormal immune profiles, including T-cell exhaustion and B-cell dysregulation (9). Herein, we report a rare case of severe acute meningoencephalitis associated with profound systemic immune dysregulation. Through longitudinal immune profiling, we characterize dynamic alterations in T-cell exhaustion, regulatory T-cell remodeling, and humoral immune abnormalities, and describe the clinical response following a combined therapeutic approach integrating IVIG and molecular hydrogen-based adjunctive therapy (HydroBox strategy) (10-12). This study was approved by the institutional review board (IRB) of Tri- Service General Hospital, National Defense Medical Center, Taiwan (IRB No. C202405129, approval date: May 12, 2024). All procedures complied with institutional guidelines and the ethical standards of the Declaration of Helsinki and its amendments. Case Report Patient characteristics and initial presentation. A 30-year-old previously healthy male was admitted to an outside hospital with acute onset of high fever, severe headache, and rapidly progressive disturbance of consciousness. According to the clinical history, the neurological symptoms evolved rapidly over a short period, progressing from altered mental status to severe encephalopathy. Within 24 hours after initial presentation, the patient’s condition deteriorated dramatically, complicated by acute hypercapnic respiratory failure and coma, requiring emergency endotracheal intubation and mechanical ventilation. Because of persistent coma, respiratory instability, and suspected severe inflammatory involvement of the central nervous system, the patient was transferred to our intensive care unit (ICU) and admitted on February 13, 2026 (Figure 1). During the acute phase, neurological examination demonstrated profound impairment of consciousness, with a Glasgow Coma Scale (GCS) score of E1V1M4. Motor examination revealed severe generalized weakness, with bilateral limb muscle strength reduced to Grade 1-2, indicating extensive neurological dysfunction (Figure 2). Clinical timeline of disease progression and therapeutic interventions. The timeline summarizes the clinical course, major therapeutic interventions, and recovery milestones. The patient was admitted on February 13, 2026, with severe acute meningoencephalitis complicated by neurological deterioration and systemic inflammation. Due to persistent encephalopathy and evidence of immune dysregulation, a combined therapeutic strategy consisting of IVIG and molecular hydrogen-based adjunctive intervention (HydroBox strategy) was initiated on February 19, 2026. Subsequent clinical improvement and inflammatory resolution were observed during the following weeks, with the patient entering the pre-discharge observation phase by March 31, 2026. IVIG: Intravenous immunoglobulin. Longitudinal changes in systemic inflammatory markers during disease progression and recovery. Serial measurements of (A) peripheral WBC counts and (B) CRP levels throughout the clinical course. During the acute phase, the patient exhibited marked leukocytosis and elevated inflammatory markers, indicating severe systemic inflammation. Following initiation of combined immunomodulatory therapy, inflammatory markers progressively declined and reached near-normal levels, paralleling clinical improvement. WBC: White blood cell; CRP: C-reactive protein. Cerebrospinal fluid and laboratory findings. Initial cerebrospinal fluid (CSF) examination performed at the outside hospital demonstrated findings compatible with acute meningoencephalitis. The CSF analysis revealed marked pleocytosis, with a white blood cell (WBC) count of 81/μl, together with elevated total protein concentration of 60.9 mg/dl. These findings suggested substantial inflammatory activation within the central nervous system and disruption of the blood-brain barrier. Following ICU admission, systemic inflammatory evaluation revealed severe immune activation. Peripheral blood examination demonstrated marked leukocytosis, with the WBC count reaching a peak value of 25.78×10³/μl. In addition, C-reactive protein (CRP) remained elevated during the early disease course, suggesting persistent systemic inflammation despite standard intensive care management (Figure 3). Temporal changes in neurological status assessed by GCS and bilateral limb muscle strength. During the acute phase of meningoencephalitis, the patient developed severe neurological impairment with reduced consciousness and motor weakness (A-E). Progressive improvement was observed after intervention, with recovery of consciousness and restoration of muscle strength to baseline levels. GCS: Glasgow Coma Scale. Longitudinal immunophenotyping. Because of the unusually severe clinical presentation and the possibility that immune dysregulation contributed to disease progression, longitudinal peripheral blood immunophenotyping was performed during the disease course. The evaluation included comprehensive analysis of T-cell differentiation states, immune checkpoint expression, regulatory T-cell populations, and B-cell subsets. These analyses demonstrated extensive alterations involving both cellular and humoral immune compartments, supporting the presence of systemic immune imbalance beyond isolated CNS inflammation. HydroBox therapeutic strategy. Given the persistent inflammatory response and immune abnormalities, a combined therapeutic strategy was initiated on February 19, 2026. The HydroBox strategy consisted of standard intensive care treatment combined with IVIG administration and molecular hydrogen-based adjunctive intervention. IVIG was selected based on the presence of abnormal humoral immune activation, while molecular hydrogen was incorporated as an adjunctive approach targeting oxidative stress-associated immune dysfunction. Clinical course and outcomes. Following initiation of the combined intervention, the patient’s clinical condition gradually improved. Systemic inflammatory markers demonstrated continuous resolution, with WBC count decreasing to 3.47×10³/μl by March 2, 2026. CRP levels progressively declined and became undetectable (<0.10 mg/dl) by mid-March (Figure 3). Neurological recovery occurred concurrently with improvement of systemic inflammation. The patient gradually regained consciousness, allowing successful ventilator weaning and extubation. By early March, neurological examination demonstrated complete recovery, with a GCS score of E4V5M6 and restoration of bilateral upper and lower extremity strength to Grade 5 (Figure 2). Follow-up CSF analysis confirmed resolution of neuroinflammation, showing a reduction in CSF WBC count from 81/μl at presentation to 8/μl. The patient subsequently entered a stable pre-discharge observation phase on March 31, 2026 (Figure 1). Discussion This case describes a severe episode of acute meningoencephalitis complicated by profound systemic immune dysregulation. Beyond the acute neurological injury, the patient’s clinical deterioration appeared to be associated with a complex immune imbalance involving uncontrolled humoral activation, extensive T-cell exhaustion, and disrupted regulatory immune homeostasis. Acute meningoencephalitis has been recognized not only as a localized central nervous system inflammatory disorder but also as a systemic immunological crisis in which excessive inflammatory activation may contribute to secondary tissue injury and neurological deterioration (13). One of the most notable findings in this case was the paradoxical dissociation between B-cell activation and effective antibody function. During the acute inflammatory phase, peripheral immunophenotyping revealed marked expansion of B-cell populations and plasmablasts, suggesting excessive humoral immune activation (Figure 4). However, this response was accompanied by an abnormally low serum immunoglobulin M (IgM) level, indicating impaired functional antibody homeostasis. Such a pattern may represent a state of dysregulated B-cell differentiation, in which activated B cells are driven toward plasmablast expansion but fail to maintain effective protective antibody production. Similar abnormalities of plasmablast expansion and humoral imbalance have been described in autoimmune and inflammatory conditions, where excessive B-cell activation contributes to immune-mediated tissue injury (14). Given this humoral abnormality, IVIG administration provided a mechanistically rational intervention. IVIG has multiple immunomodulatory effects, including Fcγ receptor (FcγR)-dependent immune regulation, suppression of pathogenic antibody-mediated inflammation, and modulation of B-cell activation pathways (15). In this case, the rapid reduction of B-cell hyperactivation following IVIG administration supports the possibility that targeting the humoral axis contributed to restoration of immune balance. Longitudinal flow cytometric analysis of PD-1 expression among Tc populations, including (A) naïve Tc, (B) central memory Tc, (C) effector Tc, and (D) effector memory Tc. During the acute inflammatory phase, marked elevation of PD-1 expression was observed across Tc subsets, indicating a profound exhausted immune phenotype. PD-1 expression gradually decreased during recovery toward healthy control levels. Whole blood analysis included a HC group for comparison, shown on the far left. Data were obtained from a single patient sample. Flow cytometric and immunophenotyping analyses were performed without biological replicates and with one technical replicate. Ten HC was included for comparison. PD-1: Programmed cell death protein 1; Tc: Cytotoxic T-cell; HC: healthy control. A major immunological feature of this case was the extensive exhaustion phenotype observed in T-cell compartments. Flow cytometric analysis demonstrated widespread elevation of inhibitory checkpoint markers, including PD-1 and Tim-3, together with KLRG1 (Figure 5 and Figure 6). T-cell exhaustion is traditionally associated with chronic antigen exposure, persistent viral infection, and tumor immunity; however, severe acute inflammatory states may induce similar phenotypic changes through sustained immune activation and metabolic stress (4). The simultaneous elevation of multiple inhibitory receptors, including PD-1 and Tim-3, suggests a state of functional suppression rather than simple immune activation (5). In this patient, exhaustion markers were observed even in naïve T-cell subsets, suggesting that the inflammatory environment extended beyond antigen-experienced populations. A possible explanation is that excessive cytokine signaling and oxidative stress during severe neuroinflammation induced mitochondrial dysfunction and metabolic impairment, accelerating immune exhaustion. Following the combined intervention, the progressive reduction of PD-1, Tim-3, and KLRG1 expression toward healthy control levels paralleled clinical recovery, suggesting restoration of T-cell immune homeostasis. Expression patterns of (A) Tim-3 in naïve helper T cells, (B) Tim-3 in naïve cytotoxic T cells, and (C) KLRG1 in naïve cytotoxic T cells. Increased expression during the acute phase suggested extensive immune stress affecting naïve immune compartments. These markers progressively declined during recovery, indicating restoration of immune homeostasis. Whole blood analysis included a HC group for comparison, shown on the far left. Data were obtained from a single patient sample. Flow cytometric and immunophenotyping analyses were performed without biological replicates and with one technical replicate. Ten HC was included for comparison. Tim-3: T-cell immunoglobulin and mucin-domain containing-3; KLRG1: killer cell lectin-like receptor g1; HC: healthy control. Changes in (A) total B-cell frequency and (B) plasmablast proportion among class-switched B-cell populations. Acute disease was associated with marked B-cell activation and plasmablast expansion accompanied by impaired antibody homeostasis. Following intervention, these abnormalities gradually normalized, suggesting recovery of humoral immune balance. Whole blood analysis included a HC group for comparison, shown on the far left. Data were obtained from a single patient sample. Flow cytometric and immunophenotyping analyses were performed without biological replicates and with one technical replicate. Ten HC was included for comparison. HC: Healthy control. The regulatory T-cell compartment demonstrated a dynamic remodeling pattern during the disease course. Acute inflammation was associated with a marked reduction in total Treg frequency, indicating impaired regulatory capacity during the inflammatory crisis. Interestingly, the remaining Tregs showed a pronounced increase in the cluster of differentiation 39 (CD39)+Helios+ suppressive phenotype (Figure 7). CD39-expressing Tregs contribute to immune suppression through extracellular adenosine triphosphate (ATP) degradation and adenosine generation, thereby limiting excessive inflammatory responses (14). Helios expression has also been associated with thymic-derived Treg stability and maintenance of suppressive function (15). The expansion of CD39+Helios+ Tregs may therefore represent an endogenous compensatory mechanism attempting to counteract overwhelming inflammation. Restoration of total Treg frequency together with normalization of the activated suppressive subset suggests recovery of regulatory immune balance. Longitudinal analysis of (A) total Tregs among CD4+ T cells and (B) CD39+Helios+ suppressive Tregs among CD3+CD4+CD25high T cells. Acute inflammation was associated with reduced total Treg frequency and compensatory expansion of suppressive CD39+Helios+ Tregs. During recovery, restoration of total Treg frequency and normalization of suppressive Treg expansion were observed. Whole blood analysis included a HC group for comparison, shown on the far left. Data were obtained from a single patient sample. Flow cytometric and immunophenotyping analyses were performed without biological replicates and with one technical replicate. Ten HC was included for comparison. Tregs: Regulatory T cells; CD4: cluster of differentiation 4; CD39: cluster of differentiation 39; CD3: cluster of differentiation 3; CD25: cluster of differentiation 25; HC: healthy control. The HydroBox strategy incorporated molecular hydrogen as an adjunctive intervention targeting oxidative stress and immune dysfunction. Recent mechanistic studies suggest that molecular hydrogen may regulate cellular signaling through TRPC4/TRPC4AP-dependent calcium modulation and influence mitochondrial electron transport chain activity through interaction with the Rieske iron-sulfur protein (8, 9). Because immune exhaustion is closely linked to metabolic dysfunction and mitochondrial stress, molecular hydrogen may theoretically contribute to immune recovery by reducing excessive oxidative burden while preserving mitochondrial function. Consistent with this hypothesis, previous clinical immunophenotyping data suggest that molecular hydrogen-assisted therapy may modulate immune abnormalities, including reduction of exhausted T-cell phenotypes and correction of abnormal B-cell activation patterns (13). In the present case, the observed normalization of exhaustion markers and immune cell distribution following HydroBox intervention provides preliminary clinical support for this immunomodulatory concept. This report is limited by its single-patient design and the concurrent use of IVIG, intensive supportive care, and molecular hydrogen intervention. Therefore, the individual contribution of each component cannot be independently determined. Further prospective studies incorporating larger cohorts, single-cell transcriptomic analysis, and metabolic profiling of immune cells are required to validate these observations and clarify the mechanisms underlying immune restoration following molecular hydrogen-based adjunctive therapy. Conclusion This case report highlights the successful management of a severe, refractory acute meningoencephalitis in a 30-year-old male through a novel, dual-axis therapeutic approach. The patient’s rapid clinical deterioration was driven by a complex immunological crisis, characterized by a paradoxical B-cell linkage (Massive plasmablast expansion coupled with functional IgM deficiency) and extreme systemic T-cell exhaustion. The integration of IVIG with the HydroBox strategy (molecular hydrogen-based adjunctive intervention) demonstrated potential synergistic effects in halting the neuroinflammatory storm. IVIG effectively addressed the humoral breakdown by neutralizing pathogenic autoantibodies and suppressing aberrant B-cell hyperactivity. Concurrently, molecular hydrogen, recognized for its potent anti-inflammatory and selective antioxidant properties, played a crucial role in mitigating intracellular oxidative stress and restoring cellular immune homeostasis. The longitudinal immunophenotyping demonstrated that hydrogen therapy facilitated the reversal of extreme T-cell exhaustion evidenced by the dramatic downregulation of PD-1, Tim-3, and KLRG1 and supported the replenishment of the collapsed Treg pool. Ultimately, the profound clinical recovery and the normalization of cerebrospinal fluid parameters emphasize the therapeutic promise of combining targeted humoral treatments with molecular hydrogen in critical neuroinflammatory crises. While this single-case observation provides compelling preliminary insights into the mechanisms of immune exhaustion and recovery, further large-scale, randomized controlled trials are imperative. Future research must focus on validating these immunomodulatory pathways, optimizing the HydroBox treatment protocols, and establishing its broader efficacy and safety in critical care immunology. Conflicts of Interest The Authors declare that they have no conflicts of interest or competing interests related to this study. Authors’ Contributions CLW: Conceptualization, methodology, writing–original draft, writing review and editing. JWL: Conceptualization, methodology, writing–original draft, writing review and editing. YJH: Conceptualization, methodology, project administration, writing–review and editing. MCW: Conceptualization, methodology, writing–review and editing. SWL: Conceptualization, methodology, writing–review and editing. TYH: Conceptualization, methodology, writing–review and editing. WLJ: Conceptualization, methodology, writing–review and editing. FCL: Conceptualization, investigation, supervision, writing–review and editing. Acknowledgements This study was supported by the National Science and Technology Council, Taiwan (grants NSTC 112-2314-B-016-033, NSTC 113-2314-B-016-052, NSTC 114-2314-B-016-052-MY3 and NSTC 114-2313-B-019-012) and Tri-Service General Hospital, Taiwan (grants TSGH-E-112218 and TSGH-E-113238). Artificial Intelligence (AI) Disclosure During the preparation of this manuscript, a large language model (ChatGPT, OpenAI) was used solely for language editing and stylistic refinement. Generative AI was not used for the generation, analysis, or interpretation of research data. All scientific content was independently developed, reviewed, and verified by the authors, who assume full responsibility for the accuracy and integrity of the work. Furthermore, no figures, images, or visual data were generated, modified, or enhanced using generative AI or machine learning–based tools.